ECSP10010417A - Inhibidores aldh-2 en el tratamiento de la adiccion - Google Patents

Inhibidores aldh-2 en el tratamiento de la adiccion

Info

Publication number
ECSP10010417A
ECSP10010417A EC2010010417A ECSP10010417A ECSP10010417A EC SP10010417 A ECSP10010417 A EC SP10010417A EC 2010010417 A EC2010010417 A EC 2010010417A EC SP10010417 A ECSP10010417 A EC SP10010417A EC SP10010417 A ECSP10010417 A EC SP10010417A
Authority
EC
Ecuador
Prior art keywords
aldh
inhibitors
addiction treatment
addiction
formula
Prior art date
Application number
EC2010010417A
Other languages
English (en)
Spanish (es)
Inventor
Jeff Zablocki
Matthew Abelman
Ivan Diamond
Mar A Pia Arolfo
Lina Yao
Peidong Fan
Elfatih Elzein
Rao Kalla
Thao Perry
Tetsuya Kobayashi
Xiaofen Li
Wing Ming Keung
Yaroslav Bilokin
Robert Jiang
Michael Organ
Zhan Jiang
Guoxin Tao
Original Assignee
Gilead Palo Alto Inc
Endowment For Res In Human Biology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Palo Alto Inc, Endowment For Res In Human Biology Inc filed Critical Gilead Palo Alto Inc
Publication of ECSP10010417A publication Critical patent/ECSP10010417A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
EC2010010417A 2008-01-24 2010-08-23 Inhibidores aldh-2 en el tratamiento de la adiccion ECSP10010417A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/051862 WO2009094028A1 (en) 2008-01-24 2008-01-24 Aldh-2 inhibitors in the treatment of addiction

Publications (1)

Publication Number Publication Date
ECSP10010417A true ECSP10010417A (es) 2010-11-30

Family

ID=39731733

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010417A ECSP10010417A (es) 2008-01-24 2010-08-23 Inhibidores aldh-2 en el tratamiento de la adiccion

Country Status (13)

Country Link
EP (1) EP2254878A1 (de)
JP (1) JP2011510072A (de)
KR (1) KR20100130589A (de)
CN (1) CN101925590A (de)
AU (1) AU2008348372A1 (de)
BR (1) BRPI0822129A2 (de)
CA (1) CA2712750A1 (de)
EC (1) ECSP10010417A (de)
IL (1) IL207127A0 (de)
MA (1) MA32095B1 (de)
MX (1) MX2010008111A (de)
WO (1) WO2009094028A1 (de)
ZA (1) ZA201004671B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102161648A (zh) * 2011-02-18 2011-08-24 中国药科大学 具有选择性雌激素受体调节活性的异黄酮类化合物的制备方法及其用途
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
AR087700A1 (es) * 2011-08-30 2014-04-09 Gilead Sciences Inc Inhibidores de aldh-2 en el tratamiento de adicciones
AU2018352215A1 (en) * 2017-10-16 2020-04-16 Amygdala Neurosciences, Inc. Combination therapy for preventing addiction
CN108276374B (zh) * 2018-03-29 2020-01-31 天津科技大学 黄酮类芳香化酶抑制剂及其制备方法与应用
CN110922394B (zh) * 2019-11-21 2021-04-06 中国科学院宁波材料技术与工程研究所 一种基于天然黄酮类化合物的生物基本征阻燃环氧树脂前驱体及其制备方法和应用
WO2023235753A2 (en) * 2022-05-31 2023-12-07 University Of Maryland, Baltimore Aldh2 inhibitors and methods of use thereof
US20230399299A1 (en) 2022-06-14 2023-12-14 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2023244574A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU162377B (de) * 1970-05-27 1973-02-28
US4166862A (en) * 1971-05-25 1979-09-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Animal feed containing anabolic isoflavones
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
CA2334830A1 (en) * 1998-05-12 1999-11-18 The Endowment For Research In Human Biology, Inc. Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
JP4933730B2 (ja) * 2001-05-04 2012-05-16 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用法
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
CN1671373A (zh) * 2002-06-27 2005-09-21 人类生物研究基金公司 用于抑制aldh的化合物
WO2006002422A2 (en) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
PL377180A1 (pl) * 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
EP2046769A2 (de) * 2006-07-27 2009-04-15 Cv Therapeutics, Inc. Aldh-2-hemmer für die suchtbehandlung
US20090124672A1 (en) * 2007-11-06 2009-05-14 Ivan Diamond Aldh-2 inhibitors in the treatment of psychiatric disorders

Also Published As

Publication number Publication date
AU2008348372A1 (en) 2009-07-30
KR20100130589A (ko) 2010-12-13
CN101925590A (zh) 2010-12-22
MX2010008111A (es) 2010-11-30
EP2254878A1 (de) 2010-12-01
JP2011510072A (ja) 2011-03-31
CA2712750A1 (en) 2009-07-30
ZA201004671B (en) 2011-03-30
IL207127A0 (en) 2010-12-30
WO2009094028A1 (en) 2009-07-30
BRPI0822129A2 (pt) 2015-06-23
MA32095B1 (fr) 2011-02-01

Similar Documents

Publication Publication Date Title
ECSP10010417A (es) Inhibidores aldh-2 en el tratamiento de la adiccion
ECSP088919A (es) Inhibidores de aldh-2 en el tratamiento de la adicción
ECSP13013087A (es) Compuestos para el tratamiento de la adicción
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
UY35177A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
UY30130A1 (es) Derivados de n-heteroaril-carboxamidas triciclicas que contienen un resto bencimidazol, su preparacion y su aplicacion en terapeutica.
CU20120013A7 (es) Derivados de oxacina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
NI201000060A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA.
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
UY31606A1 (es) Derivados de carboxamidas azabicíclicas, su preparación y su aplicación en terapéutica
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
UY32432A (es) Compuestos de pirimidina fusionada como inhibidores de akt
BR112012031508A2 (pt) composição e uso da mesma
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
UY31645A1 (es) Nuevas imidazolidinas fenil-sustituidas, procedimiento para su preparación, medicamentos que conprenden dichos compuestos y su uso.
CO6650413A2 (es) Conjugador para prevención o el tratamiento de la adicción a la nicotina
UY32404A (es) 4-aril-butan-1,3-diamidas
CR11759A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
HN2012001262A (es) Nuevos derivados de 8heterociclo-piperidina condensada)-( piperazinil)-1-alcanona o de (heterociclo-pirrolidina condensada)-(piperazinil)-1-alcanona y su utilizacion como inhibidores de p75
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
EA201490270A1 (ru) Ингибиторы aldh-2 для лечения зависимости